# US Cannabis Companies Could ‘Ring the Bell’ at US Stock Markets Under New Bill > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/public-market-access-cannabis-companies-new-bill/ > **Published:** 2026-03-23T16:04:08-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:41:21-04:00 > **Clinical Summary:** Public market access cannabis companies could transform the industry with new bill provisions enabling stock market listings and institutional investment. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic RegulationProduct QualityIndustry StandardsAccessPolicy Why This Matters Public market access for cannabis companies would fundamentally alter the industry’s capital structure, potentially accelerating research and development of standardized medical products. This represents a shift from cash-intensive, locally-regulated businesses toward companies with institutional oversight and reporting requirements that could improve product consistency and safety data. Clinical Summary Legislative proposals would allow US cannabis companies to list on major stock exchanges, currently prohibited due to federal cannabis scheduling. Public markets require standardized financial reporting, regulatory compliance, and institutional governance structures. This could drive consolidation toward larger, more regulated entities with resources for [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/), quality control systems, and standardized manufacturing processes. The change would not alter cannabis’s federal legal status but would remove a significant barrier to institutional investment. Dr. Caplan’s Take “Better capitalized cannabis companies with institutional oversight could mean more consistent products and actual [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) funding. But it also means Wall Street metrics driving decisions about what gets developed and what doesn’t.” Clinical Perspective 🧠 Clinicians should watch for improved product standardization and third-party testing as publicly-traded companies face greater accountability. However, market-driven product development may prioritize recreational appeal over therapeutic efficacy. [Patient access](https://cedclinic.com/iowa-medical-cannabis-dispensaries-expansion/) and pricing could shift significantly as institutional investors enter the market. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20US%20Cannabis%20Companies%20Could%20%27Ring%20the%20Bell%27%20at%20US%20Stock%20Markets%20Under%20New%20Bill%20%40drcaplan&url=https%3A//www.cannabisbusinesstimes.com/finance/news/15820356/us-cannabis-companies-could-ring-the-bell-at-us-stock-markets-under-new-bill)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//www.cannabisbusinesstimes.com/finance/news/15820356/us-cannabis-companies-could-ring-the-bell-at-us-stock-markets-under-new-bill)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20US%20Cannabis%20Companies%20Could%20%27Ring%20the%20Bell%27%20at%20US%20Stock%20Markets%20Under%20New%20Bill%20--%20via%20%40drcaplan.bsky.social%20https%3A//www.cannabisbusinesstimes.com/finance/news/15820356/us-cannabis-companies-could-ring-the-bell-at-us-stock-markets-under-new-bill)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.cannabisbusinesstimes.com/finance/news/15820356/us-cannabis-companies-could-ring-the-bell-at-us-stock-markets-under-new-bill](https://www.cannabisbusinesstimes.com/finance/news/15820356/us-cannabis-companies-could-ring-the-bell-at-us-stock-markets-under-new-bill) Table of Contents - [FAQ](#FAQ)[What is the clinical relevance rating for this cannabis news?](#What_is_the_clinical_relevance_rating_for_this_cannabis_news) - [What key areas does this cannabis news cover?](#What_key_areas_does_this_cannabis_news_cover) - [Why is this news marked as “New” for clinicians?](#Why_is_this_news_marked_as_8220New8221_for_clinicians) - [What does “Notable Clinical Interest” mean for healthcare providers?](#What_does_8220Notable_Clinical_Interest8221_mean_for_healthcare_providers) - [How does this relate to the CED Clinic’s cannabis coverage?](#How_does_this_relate_to_the_CED_Clinic8217s_cannabis_coverage) - [Related](#Related) ## FAQ #### What is the clinical relevance rating for this cannabis news? This article has been assigned CED Clinical Relevance #70, indicating “Notable Clinical Interest.” This rating suggests the content contains emerging findings or policy developments that healthcare professionals should monitor closely. #### What key areas does this cannabis news cover? The article focuses on four main areas: regulation, product quality, industry standards, and access. These topics are particularly relevant for clinical practitioners working with [cannabis-based treatments](https://cedclinic.com/cannabis-medical-clinic-experience-beyond-smoking-vaping/). #### Why is this news marked as “New” for clinicians? The “New” designation indicates this is recent information that may impact [clinical practice](https://cedclinic.com/cannabis-reproductive-health-women-clinical-evidence/) or [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/). Healthcare providers should stay current with these developments to provide informed guidance to patients. #### What does “Notable Clinical Interest” mean for healthcare providers? This classification means the information contains emerging findings or policy changes worth monitoring closely. It suggests the content may influence future clinical decisions or treatment protocols involving cannabis. #### How does this relate to the CED Clinic’s cannabis coverage? This article is part of the CED Clinic’s ongoing cannabis news coverage, focusing on clinically relevant developments. The clinic tracks regulatory changes, quality standards, and access issues that impact [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) and treatment options. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “US Cannabis Companies Could ‘Ring the Bell’ at US Stock Markets Under New Bill”, “url”: “https://www.cannabisbusinesstimes.com/finance/news/15820356/us-cannabis-companies-could-ring-the-bell-at-us-stock-markets-under-new-bill”, “datePublished”: “2026-03-23T19:34:51Z”, “about”: “us cannabis companies could ring bell”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Cannabis Companies Ended 2025 with Weakening Financial Positions](https://cedclinic.com/industry-financial-instability-cannabis-2025-impact/) An analysis of the financial challenges faced by cannabis companies at the end of 2025, highlighting industry trends and investment risks. [Read More](https://cedclinic.com/industry-financial-instability-cannabis-2025-impact/) [How U.S. marijuana reclassification could help cannabis companies – The Detroit News](https://cedclinic.com/federal-cannabis-reclassification-benefits/) Explores the potential benefits of marijuana reclassification for cannabis companies, including improved market access and regulatory relief. [Learn More](https://cedclinic.com/federal-cannabis-reclassification-benefits/) White House pushes imminent easing of controls on marijuana – The Washington Post Details the White House's efforts to ease marijuana controls, which could impact cannabis companies and market dynamics. Discover More ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).